Video
The Impact of COVID-19 and Vaccinations for MS Patients: Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCI
The senior consultant for the department of neurology at the National Neuroscience Institute shared more details about his presentation that he gave at the 38th ECTRIMS Congress. [WATCH TIME: 6 minutes]
WATCH TIME: 6 minutes
“We are now analyzing the results on patients who have received a third dose of vaccination and also analyzing their relationship, in a sense, the response to infection and the relationship to subsequent COVID infection.”
Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCI, one of the several attendees at the 38th 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress held in Amsterdam, Netherlands from October 26-28, presented on neutralizing antibodies in patients living with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or another neuroimmunological disorder who’ve received SARS-CoV-2 mRNA vaccinations.
Yeo and colleagues conducted a prospective observational study that included patients with MS (n = 77), NMOSD (n = 33), myelin oligodendrocyte glycoprotein-antibody associated disease (n = 6), autoimmune encephalitis (n = 3), other CNS inflammatory diseases (n = 5), myasthenia gravis (n = 9) and healthy controls (HCs, n = 42).1 From the study's findings, fingolimod and anti-CD20 therapies showed an associated with attenuated neutralizing antibody levels post-vaccination.
Yeo, a senior consultant in the department of neurology at the National Neuroscience Institute in Singapore, discussed that there should be more future research done on vaccines and patients with MS. He also further explained how his study’s results change the way clinicians will go about approaching COVID-19 vaccines.
In an interview with NeurologyLive®, Yeo spoke about his presentation from his ECTRIMS poster session and how generalizable the results are to other countries. He also provided commentary on whether there were any complications with the vaccinations after administration and what the focus on future MS- and NMOSD-related research should be based on the impact of the COVID-19 pandemic.
Click here for more coverage of ECTRIMS 2022.
REFERENCES
1. Yeo T, Siew R.W.E., Yaassum Gulam M et al. Longitudinal quantification of neutralising antibodies after two doses of SARS-CoV-2 mRNA vaccine in MS, NMOSD and other neuroimmunological diseases. Presented at: 2022 ECTRIMS Congress; October 26-28; Amsterdam, Netherlands. Abstract 1061
